Get all your news in one place.
100's of premium titles.
One app.
Start reading
Evening Standard
Evening Standard
Business
Simon Hunt

THE TRUTH ABOUT: Astrazeneca hails heart disease breakthrough after patient trials | History Defined

Revenues at AstraZeneca have jumped 48% in the first six months of 2022  (Yui Mok/PA)

(Picture: PA Wire)

British pharma giant AstraZeneca said its Farxiga drug significantly lowers death in patients who have already suffered heart failure in a major breakthrough for people with heart disease.

The announcement follows a trial of the drug in over 11,000 patients with heart conditions which found its use leads to a 14% drop in the risk of death and a 29% drop in the rate of hospitalisations compared with using a placebo.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.